Shuttle Pharmaceuticals Holdings Inc. Common Stock (SHPH)

FairStock Score: 39/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style analyst, looking first for a durable business and a margin of safety. Shuttle Pharmaceuticals is a clinical-stage drug developer with no reported revenue in the filings shown. Its net loss widened from $6.6 million in fiscal year 2023 to $9.1 million in fiscal year 2024 and $11.7 million in fiscal year 2025. In fiscal Q2 2026, the quarter ended 2026-06-30, it lost $3.1 million, or $3.10 per diluted share. That is not a compounding earnings machine; it is a cash-consuming research effort. The company describes an AI-driven molecular discovery platform, but with just two employees and no revenue, I cannot identify a durable competitive moat or pricing power. Financial health is poor: trailing free cash flow is negative $12.5 million, a negative 50.5% free cash flow yield on its $24.7 million market cap; return on equity is negative 90.05% and return on capital employed negative 49.54%. The FairStock Piotroski score is 2/9 and Altman Z-score is negative 4.59, both warning signs. On valuation, the $5.18 close on 2026-10-13 gives a FairStock P/B of 0.86, which looks superficially asset-backed, but the Graham Number is $3.68, implying a negative 40.76% margin of safety. The FairStock Score is 39/100, and the Lynch category is none because it lost money in each of the last four years. Profit growth of 29.50% is noted, but losses remain large and revenue is absent. Growth trajectory depends entirely on clinical and financing luck, not on present earnings. I see speculation, not a value investment with a margin of safety.

In plain English: Shuttle Pharmaceuticals is a tiny clinical-stage company trying to develop new cancer treatments; it has only two employees and no reported revenue. It has lost money every year for at least the last four years and is using cash. At $5.18, the shares look expensive compared with the company's losses and weak financial scores, even though the price is below the value of its stated assets.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer